Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
about
Advances in the development of thrombin inhibitorsSuccessful recovery after an overdose of argatroban.Oral direct thrombin inhibitors in clinical development.Current and future antithrombotic agents in children.Ximelagatran: a new antithrombotic option in atrial fibrillation.Ximelagatran: an oral direct thrombin inhibitor.Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.Association of bleeding and thrombosis with outcome in extracorporeal life support.Ximelagatran for stroke prevention in atrial fibrillation.Preclinical trauma studies of recombinant factor VIIa.Recombinant activated factor VII and the anaesthetist.Management of bleeding emergencies: when to use recombinant activated factor VII.Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studiesPractical aspects of the oral new anticoagulants.Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trial.Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats.Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban.Activated prothrombin complex concentrate for dabigatran-associated bleeding.Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate.
P2860
Q28182480-A52C8805-6F49-4A6E-A81E-57F1D7A096DCQ33370151-F41672C7-16DC-4C95-A347-845D78141F2AQ35219373-5CF8C074-EB14-4F54-910F-2A262BEA59E7Q35821894-BA3EAF6A-10C5-46E9-8989-8EA8409E1A92Q35892171-60CE5E33-6597-408F-905E-CD1CC09DC251Q35895188-85722CF1-EDD2-49EB-BF41-09B0E646B00FQ35996015-AB005E7A-07B1-4BA6-9734-8B99EE6E8432Q36161716-0E44A0A6-C2AF-48E1-878D-B48988F7E797Q36216784-FD97AE2D-D2BD-4C78-BD11-DFB3AC5B10A8Q36284643-6C240689-EC0A-42AE-826A-CFBF7943E6A7Q36313315-EBF84894-5266-4CDC-A3C9-99BEF84BD847Q36349585-E934F40B-3FE7-4544-BC14-B3FBCCDD914CQ36984232-6B482C24-E73D-4DEB-A409-DE145B28550BQ37889781-FE33F1C1-CA6C-4668-86AE-F65C88A24473Q38107945-4223CFB7-F433-4906-9DE3-9581F4EC43CDQ40972656-382C7FB8-438B-49E8-9429-46A56AF619A5Q45869716-D4F40F3E-BA95-4881-A4D2-19891784E0A0Q47243999-EC0A485D-04BB-4FAD-9081-FFA2031508C4Q48341889-FCCAC279-C4A6-40BF-A071-45DECE566789Q48599279-856AB893-8A15-4A6C-B905-806903BDCC45Q50050577-B6B944EB-EDB9-4834-B009-F3020E57928EQ53084350-FF47CC00-7088-4C7F-8DBD-76C69D723242Q53160398-747986B4-D3AB-4C45-A26E-68346D9C4E32
P2860
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effect of activated prothrombi ...... h a direct thrombin inhibitor.
@ast
Effect of activated prothrombi ...... h a direct thrombin inhibitor.
@en
type
label
Effect of activated prothrombi ...... h a direct thrombin inhibitor.
@ast
Effect of activated prothrombi ...... h a direct thrombin inhibitor.
@en
prefLabel
Effect of activated prothrombi ...... h a direct thrombin inhibitor.
@ast
Effect of activated prothrombi ...... h a direct thrombin inhibitor.
@en
P2093
P1433
P1476
Effect of activated prothrombi ...... h a direct thrombin inhibitor.
@en
P2093
P304
P356
10.1016/S0049-3848(00)00397-2
P577
2001-02-01T00:00:00Z